The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis

doi:10.3877/cma.j.issn.2096-0263.2020.01.011

Abstract

Abstract:

Objective

This study aimed toinvestigate the underlying mechanisms, and the prognostic value of long non coding RNA taurine-upregulated gene 1 (lncRNA, TUG1)inthe development and progression of osteosarcoma.

Methods

PubMed, Embase, Web of Science, Cochrane Library, ChinaNational Knowledge Internet (CNKI) and Wanfang database were systematically searched for the relevant literature of TUG1 in the development and prognosis of osteosarcoma. STATA12 (Stata Corp, College Station, Texas) was used to estimate pooled effects and the heterogeneity among studies.

Results

Current studies indicated that TUG1 regulates the proliferation, apoptosis, and invasion by acting as a ceRNA. The underlying mechanisms include AKT and Wnt/β-catenin signal pathways. Four records with a total of 244 osteosarcoma patients were enrolled in this study. The pooled results showed that the patients with high TUG1 expression had shorter overall survival (OS) compared to the patients with low TUG1 expression (OR=1.921, 95% CI: 1.361, 2.712, P=0.000). Moreover, elevated TUG1 expression was associated with advanced tumor size (OR=4.084, 95% CI: 2.313, 7.211, P=0.000), clinical stage (OR=0.258, 95%CI: 0.098, 0.682, P=0.006), and early distant metastasis (OR=1.943, 95% CI: 1.130, 3.339, P=0.016). Nevertheless, high TUG1 expression was not related to gender (OR=1.055, 95% CI: 0.620, 1.793, P=0.844) and anatomical dislocation (OR=0.806, 95% CI: 0.424, 1.530, P=0.509).

Conclusions

LncRNA TUG1 plays an important role in the molecular mechanisms of osteosarcoma. Elevated TUG1 expression indicates poor OS and clinical parameters in patients undergoing osteosarcoma, which may be used as a moderate prognostic biomarker in human osteosarcoma.

Key words: TUG1 long noncoding RNA, human, Osteosarcoma, Prognosis, Meta-analysis

Hong Sun, Qiao Yu, Guping Mao, Peng Yang, Xin Wu, Xu Ning, Hua Yang. The role and prognostic value of long noncoding RNA TUG1 in human osteosarcoma: A systematic review and meta-analysis[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2020, 06(01): 56-61.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2020.01.011

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2020/V06/I01/56

Figures/Tables 5

References 26

1	Rickel K, Fang F, Tao JN. Molecular genetics of osteosarcoma [J]. Bone, 2017, 102(SI): 69-79.
2	Miller BJ, Gao YB, Duchman KR. Socioeconomic measures influence survival in osteosarcoma: an analysis of the National Cancer Data Base [J]. Cancer Epidemiol, 2017, 49(8): 112-117.
3	Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.
4	孙红，张志奇，傅明. 长链非编码RNA在骨关节炎与骨肿瘤领域的研究进展 [J]. 中国骨与关节杂志, 2016, 5(5): 397-400.
5	Li JP, Liu LH, Li J, et al. Microarray expression profile of long noncoding RNAs in human osteosarcoma [J]. Biochem Biophys Res Commun, 2013, 433(2): 200-206.
6	Zhang Q, Geng PL, Yin P, et al. Down-regulation of long non-coding RNA TUG1 inhibits osteosarcoma cell proliferation and promotes apoptosis [J]. Asian Pac J Cancer Prev, 2013, 14(4): 2311-2315.
7	Wang HP, Yu YZ, Fan SX, et al. Knockdown of long noncoding RNA TUG1 inhibits the proliferation and cellular invasion of osteosarcoma cells by sponging miR-153 [J]. Oncol Res, 2018, 26(5): 665-673.
8	Wang Y, Yang T, Zhang Z, et al. Long non-coding RNA TUG1 promotes migration and invasion by acting as a ceRNA of miR-335-5p in osteosarcoma cells [J]. Cancer Sci, 2017, 108(5): 859-867.
9	Li G, Liu KY, Du XH. Long Non-Coding RNA TUG1 promotes proliferation and inhibits apoptosis of osteosarcoma cells by sponging miR-132-3p and upregulating SOX4 expression [J]. Yonsei Med J, 2018, 59(2): 226-235.
10	Young TL, Matsuda T, Cepko CL. The noncoding RNA taurine upregulated gene 1 is required for differentiation of the murine retina [J]. Curr Biol, 2005, 15(6): 501-512.
11	Wang QL, Chen Q. Role of taurine upregulated gene 1 as a predictor of poor outcome in osteosarcoma [J]. J Cancer Res Ther, 2018, 14(2): S405-S409.
12	Ma B, Li M, Zhang L, et al. Upregulation of long non-coding RNA TUG1 correlates with poor prognosis and disease status in osteosarcoma [J]. Tumor Biology, 2016, 37(4): 4445-4455.
13	Yu X, Hu L, Li SY, et al. Long non-coding RNA Taurine upregulated gene 1 promotes osteosarcoma cell metastasis by mediating HIF-1 alpha via miR-143-5p [J]. Cell Death Dis, 2019, 10(4): 280.
14	Hu TZ, Fei ZH, Su HF, et al. Polydatin inhibits proliferation and promotes apoptosis of doxorubicin-resistant osteosarcoma through LncRNA TUG1 mediated suppression of Akt signaling [J]. Toxicol Appl Pharmacol, 2019, 371(5): 55-62.
15	Han XF, Yang YM, Sun YJ, et al. LncRNA TUG1 affects cell viability by regulating glycolysis in osteosarcoma cells [J]. Gene, 2018, 674(10): 87-92.
16	Xie CH, Chen B, Wu B, et al. LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis [J]. Biomed Pharmacother, 2018, 97(1): 1645-1653.
17	Cao JQ, Han XY, Qi X, et al. TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via mild-144-3p [J]. Int J Oncol, 2017, 51(4): 1115-1123.
18	Yang GH, Zhang C, Wang N, et al. miR-425-5p decreases LncRNA MALAT1 and TUG1 expressions and suppresses tumorigenesis in osteosarcoma via Wnt/beta-catenin signaling pathway [J]. Int J Biochem Cell Biol, 2019, 111(6): 42-51.
19	Li Y, Zhang T, Zhang YH, et al. Targeting the FOXM1-regulated long noncoding RNA TUG1 in osteosarcoma [J]. Cancer Sci, 2018, 109(10): 3093-3104.
20	Feng YB, Xiao-Po L, Xiao-Li L, et al. LncRNA TUG1 is upregulated and promotes cell proliferation in osteosarcoma [J]. Open Med, 2016, 11(1): 163-167.
21	Xie CH, Cao YM, Huang Y, et al. Long non-coding RNA TUG1 contributes to tumorigenesis of human osteosarcoma by sponging miR-9-5p and regulating POU2F1 expression [J]. Tumor Biology, 2016, 37(11): 15031-15041.
22	Li H, Tian GF, Tian FP, et al. Long non-coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA-212-3p expression [J]. Exp Ther Med, 2018, 16(2): 779-787.
23	Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function [J]. Nat Rev Genet, 2016, 17(1): 47-62.
24	Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development [J]. Nat Rev Genet, 2014, 15(1): 7-21.
25	Bolha L, Ravnik-Glavac M, Glavac D. Long noncoding RNAs as biomarkers in cancer [J]. Dis Markers, 2017,5: 7243968.
26	Smolle MA, Pichler M. The Role of Long Non-Coding RNAs in Osteosarcoma[J]. Noncoding RNA, 2018,4(1):7.

文献	国家	样本量（女/男）	方法	表达升高（例/百分比）	HR	肿瘤大小（cm）	NOS评分
Wang等^[8]	中国	44（23/21）	qRT-PCR	30/68.18%	计算	≥5	6
Wang等^[11]	中国	94（24/70）	qRT-PCR	47/50.00%	报道	≥8	7
Ma等^[12]	中国	76（27/49）	qRT-PCR	41/53.95%	计算	≥8	6
Yu等^[13]	中国	40（22/18）	qRT-PCR	20/50.00%	报道	>8	7

文献	国家	样本量（女/男）	方法	表达升高（例/百分比）	HR	肿瘤大小（cm）	NOS评分
Wang等^[8]	中国	44（23/21）	qRT-PCR	30/68.18%	计算	≥5	6
Wang等^[11]	中国	94（24/70）	qRT-PCR	47/50.00%	报道	≥8	7
Ma等^[12]	中国	76（27/49）	qRT-PCR	41/53.95%	计算	≥8	6
Yu等^[13]	中国	40（22/18）	qRT-PCR	20/50.00%	报道	>8	7

文献	靶分子	细胞机制	细胞通路
Zhang等^[6]	未提及	细胞增殖（+）、凋亡（-）	未提及
Wang等^[7]	miR-153	细胞活性、侵袭（+）	未提及
Wang等^[8]	miR-335-5p/ROCK1	肿瘤迁移、侵袭（+）	未提及
Li等^[9]	miRNA-132-3p/SOX4	细胞增殖（+）、凋亡（-）	未提及
Yu等^[13]	miR-143-5p/HIF-1α	肿瘤转移、血管形成、增殖（+）	未提及
Hu等^[14]	未提及	细胞增殖（+）、凋亡（-）	AKT信号通路
Han等^[15]	hexokinase-2	糖酵解、细胞活性（+）	未提及
Xie等^[16]	miR-212-3p/ FOXA1	细胞增殖（+）、凋亡（-）	未提及
Cao等^[17]	miR-144-3p/EZH2	细胞增殖、迁移（+）	Wnt/β-catenin信号通路
Yang等^[18]	miR-425-5p	细胞增殖、肿瘤形成（+）	Wnt/β-catenin信号通路
Li等^[19]	miR-219a-5p	细胞增殖、迁移（+）	AKT信号通路
Feng等^[20]	未提及	细胞活性、增殖（+）	AKT信号通路
Xie等^[21]	miR-9-5p/POU2F1	细胞增殖（+）、凋亡（-）	未提及
Li等^[22]	miR-212-3p	细胞增殖、侵袭（+）	未提及

文献	靶分子	细胞机制	细胞通路
Zhang等^[6]	未提及	细胞增殖（+）、凋亡（-）	未提及
Wang等^[7]	miR-153	细胞活性、侵袭（+）	未提及
Wang等^[8]	miR-335-5p/ROCK1	肿瘤迁移、侵袭（+）	未提及
Li等^[9]	miRNA-132-3p/SOX4	细胞增殖（+）、凋亡（-）	未提及
Yu等^[13]	miR-143-5p/HIF-1α	肿瘤转移、血管形成、增殖（+）	未提及
Hu等^[14]	未提及	细胞增殖（+）、凋亡（-）	AKT信号通路
Han等^[15]	hexokinase-2	糖酵解、细胞活性（+）	未提及
Xie等^[16]	miR-212-3p/ FOXA1	细胞增殖（+）、凋亡（-）	未提及
Cao等^[17]	miR-144-3p/EZH2	细胞增殖、迁移（+）	Wnt/β-catenin信号通路
Yang等^[18]	miR-425-5p	细胞增殖、肿瘤形成（+）	Wnt/β-catenin信号通路
Li等^[19]	miR-219a-5p	细胞增殖、迁移（+）	AKT信号通路
Feng等^[20]	未提及	细胞活性、增殖（+）	AKT信号通路
Xie等^[21]	miR-9-5p/POU2F1	细胞增殖（+）、凋亡（-）	未提及
Li等^[22]	miR-212-3p	细胞增殖、侵袭（+）	未提及

观察指标	文献数	样本量		HR/OR，95% CI	P值	异质性
观察指标	文献数	升高组	降低组	HR/OR，95% CI	P值	I²	P_Q
总体生存率	3	118	96	1.903（1.328-2.728）	0.00	25%	0.264
性别	3	118	96	1.268（0.708-2.268）	0.424	0	0.303
肿瘤大小	3	118	96	3.823（2.071-7.055）	0.000	26.5%	0.209
肿瘤临床分级	2	77	61	0.258（0.098-0.682）	0.006	0	0.000
肿瘤发生部位	3	118	96	0.693（0.369-1.300）	0.253	0	0.507
肿瘤远处转移	3	118	96	1.775（0.727-4.333）	0.208	52.9%	0.142

Please choose a citation manager

Content to export